EP Patent

EP4292594A2 — Inhibitors of ret

Assigned to Blueprint Medicines Corp · Expires 2023-12-20 · 2y expired

What this patent protects

Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

USPTO Abstract

Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP4292594A2
Jurisdiction
EP
Classification
—
Expires
2023-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.